Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma

George T. Henning, Steven E. Schild, Scott L. Stafford, John H. Donohue, Patrick A. Burch, Michael Haddock, Leonard L. Gunderson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To evaluate the results of irradiation ± chemotherapy for patients with unresectable gastric carcinoma. Materials and Methods: The records of 60 patients with a gastric or gastroesophageal junction adenocarcinoma and a locally advanced unresectable primary (n = 28), a local or regional recurrence (n = 21), or gross residual disease following incomplete resection (n = 11) were retrospectively reviewed. Patients were treated with external beam irradiation (EBRT) alone or external beam plus intraoperative irradiation (IOERT), and 55 of the 60 (92%) patients received 5-FU based chemotherapy.Results: The median survival for the entire cohort was 11.6 months. There was no significant difference in median survival between each of the three treatment groups. In examining the extent of disease there was a significant difference in survival based on the number of sites involved. Nine patients with disease limited to a single non-nodal site appeared to represent a favorable subgroup compared to the rest of the patients (median survival of 21.8 months vs. 10.2 months, p = 0.03). In the patients with recurrent disease, the number of sites involved (p = 0.05), and total dose adding external beam dose to IOERT dose (> 54 Gy vs. ≤ 54 Gy, p = 0.06) were of borderline significance in regard to survival.Conclusions: In patients with either primary unresectable, locally or regionally recurrent, or incompletely resected gastric carcinoma, the overall survival is similar, and related to the extent of disease based on the number of regional sites involved. The patients with a single non-nodal site of disease represent a favorable subgroup and patients with recurrent disease may benefit from total irradiation doses > 54 Gy. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume46
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Stomach
Adenocarcinoma
irradiation
Survival
dosage
chemotherapy
subgroups
cancer
Carcinoma
Drug Therapy
Esophagogastric Junction
Fluorouracil
Recurrence

Keywords

  • Combined modality therapy
  • IORT
  • Radiotherapy
  • Stomach neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. / Henning, George T.; Schild, Steven E.; Stafford, Scott L.; Donohue, John H.; Burch, Patrick A.; Haddock, Michael; Gunderson, Leonard L.

In: International Journal of Radiation Oncology Biology Physics, Vol. 46, No. 1, 01.01.2000, p. 109-118.

Research output: Contribution to journalArticle

Henning, George T. ; Schild, Steven E. ; Stafford, Scott L. ; Donohue, John H. ; Burch, Patrick A. ; Haddock, Michael ; Gunderson, Leonard L. / Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. In: International Journal of Radiation Oncology Biology Physics. 2000 ; Vol. 46, No. 1. pp. 109-118.
@article{99f26d6a593344df9f782b5dd58b0f52,
title = "Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma",
abstract = "Objective: To evaluate the results of irradiation ± chemotherapy for patients with unresectable gastric carcinoma. Materials and Methods: The records of 60 patients with a gastric or gastroesophageal junction adenocarcinoma and a locally advanced unresectable primary (n = 28), a local or regional recurrence (n = 21), or gross residual disease following incomplete resection (n = 11) were retrospectively reviewed. Patients were treated with external beam irradiation (EBRT) alone or external beam plus intraoperative irradiation (IOERT), and 55 of the 60 (92{\%}) patients received 5-FU based chemotherapy.Results: The median survival for the entire cohort was 11.6 months. There was no significant difference in median survival between each of the three treatment groups. In examining the extent of disease there was a significant difference in survival based on the number of sites involved. Nine patients with disease limited to a single non-nodal site appeared to represent a favorable subgroup compared to the rest of the patients (median survival of 21.8 months vs. 10.2 months, p = 0.03). In the patients with recurrent disease, the number of sites involved (p = 0.05), and total dose adding external beam dose to IOERT dose (> 54 Gy vs. ≤ 54 Gy, p = 0.06) were of borderline significance in regard to survival.Conclusions: In patients with either primary unresectable, locally or regionally recurrent, or incompletely resected gastric carcinoma, the overall survival is similar, and related to the extent of disease based on the number of regional sites involved. The patients with a single non-nodal site of disease represent a favorable subgroup and patients with recurrent disease may benefit from total irradiation doses > 54 Gy. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Combined modality therapy, IORT, Radiotherapy, Stomach neoplasms",
author = "Henning, {George T.} and Schild, {Steven E.} and Stafford, {Scott L.} and Donohue, {John H.} and Burch, {Patrick A.} and Michael Haddock and Gunderson, {Leonard L.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0360-3016(99)00379-X",
language = "English (US)",
volume = "46",
pages = "109--118",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma

AU - Henning, George T.

AU - Schild, Steven E.

AU - Stafford, Scott L.

AU - Donohue, John H.

AU - Burch, Patrick A.

AU - Haddock, Michael

AU - Gunderson, Leonard L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Objective: To evaluate the results of irradiation ± chemotherapy for patients with unresectable gastric carcinoma. Materials and Methods: The records of 60 patients with a gastric or gastroesophageal junction adenocarcinoma and a locally advanced unresectable primary (n = 28), a local or regional recurrence (n = 21), or gross residual disease following incomplete resection (n = 11) were retrospectively reviewed. Patients were treated with external beam irradiation (EBRT) alone or external beam plus intraoperative irradiation (IOERT), and 55 of the 60 (92%) patients received 5-FU based chemotherapy.Results: The median survival for the entire cohort was 11.6 months. There was no significant difference in median survival between each of the three treatment groups. In examining the extent of disease there was a significant difference in survival based on the number of sites involved. Nine patients with disease limited to a single non-nodal site appeared to represent a favorable subgroup compared to the rest of the patients (median survival of 21.8 months vs. 10.2 months, p = 0.03). In the patients with recurrent disease, the number of sites involved (p = 0.05), and total dose adding external beam dose to IOERT dose (> 54 Gy vs. ≤ 54 Gy, p = 0.06) were of borderline significance in regard to survival.Conclusions: In patients with either primary unresectable, locally or regionally recurrent, or incompletely resected gastric carcinoma, the overall survival is similar, and related to the extent of disease based on the number of regional sites involved. The patients with a single non-nodal site of disease represent a favorable subgroup and patients with recurrent disease may benefit from total irradiation doses > 54 Gy. Copyright (C) 2000 Elsevier Science Inc.

AB - Objective: To evaluate the results of irradiation ± chemotherapy for patients with unresectable gastric carcinoma. Materials and Methods: The records of 60 patients with a gastric or gastroesophageal junction adenocarcinoma and a locally advanced unresectable primary (n = 28), a local or regional recurrence (n = 21), or gross residual disease following incomplete resection (n = 11) were retrospectively reviewed. Patients were treated with external beam irradiation (EBRT) alone or external beam plus intraoperative irradiation (IOERT), and 55 of the 60 (92%) patients received 5-FU based chemotherapy.Results: The median survival for the entire cohort was 11.6 months. There was no significant difference in median survival between each of the three treatment groups. In examining the extent of disease there was a significant difference in survival based on the number of sites involved. Nine patients with disease limited to a single non-nodal site appeared to represent a favorable subgroup compared to the rest of the patients (median survival of 21.8 months vs. 10.2 months, p = 0.03). In the patients with recurrent disease, the number of sites involved (p = 0.05), and total dose adding external beam dose to IOERT dose (> 54 Gy vs. ≤ 54 Gy, p = 0.06) were of borderline significance in regard to survival.Conclusions: In patients with either primary unresectable, locally or regionally recurrent, or incompletely resected gastric carcinoma, the overall survival is similar, and related to the extent of disease based on the number of regional sites involved. The patients with a single non-nodal site of disease represent a favorable subgroup and patients with recurrent disease may benefit from total irradiation doses > 54 Gy. Copyright (C) 2000 Elsevier Science Inc.

KW - Combined modality therapy

KW - IORT

KW - Radiotherapy

KW - Stomach neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0033981519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033981519&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(99)00379-X

DO - 10.1016/S0360-3016(99)00379-X

M3 - Article

C2 - 10656381

AN - SCOPUS:0033981519

VL - 46

SP - 109

EP - 118

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -